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Abstract
Background: Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim of this study is
to investigate whether specific treatment reverts ACL-associated renal dysfunction.
Methods: A prospective study was conducted with 37 patients with ACL. Urinary concentrating and acidification
ability was assessed before and after treatment with pentavalent antimonial.
Results: The patients mean age was 35.6 ± 12 years and 19 were male. Before treatment, urinary concentrating
defect (U/Posm <2.8) was identified in 27 patients (77%) and urinary acidification defect in 17 patients (46%). No
significant glomerular dysfunction was observed before and after specific ACL treatment. There was no reversion of
urinary concentrating defects, being observed in 77% of the patients before and in 88% after treatment (p = 0.344).
Urinary acidification defect was corrected in 9 patients after treatment, reducing its prevalence from 40% before to
only 16% after treament, (p = 0.012). Microalbuminuria higher than 30 mg/g was found in 35% of patients before
treatment and in only 8% after treatment. Regarding fractional excretion of sodium, potassium, calcium, phosphorus
and magnesium, there was no significant difference between pre and post-treatment period.
Conclusion: As previously described, urinary concentrating and acidification defects were found in an important
number of patients with ACL. Present results demonstrate that only some patients recover urinary acidification
capacity, while no one returned to normal urinary concentration capacity.
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Background
Leishmaniasis is a parasitic disease caused by Leishmania
species which could manifest as visceral, mucous or
cutaneous involvement, depending on the host immune
response [1-4].
It is estimated that 1.5 to 2 million people develop
symptomatic disease each year [5]. American Cutaneous
Leishmaniasis (ACL) is endemic in some countries in
Africa, Middle East, Europe and Latin America, represent-
ing a Public Health problem, not only due to its high inci-
dence, but also due to its potential to cause destructive
and incapacitating lesions, with high psychosocial impact
[4,6].
Renal involvement has been described in visceral
leishmaniasis (kala-azar), including from mild urinary
abnormalities to severe glomerular involvement and
renal failure [7-10]. Renal failure in kala-azar is thought
to occur due to interstitial nephritis secondary to im-
mune complex deposition and hypersensitivity to penta-
valent antimonials [6,11-13]. Tubular dysfunction has
also been described in kala-azar as urinary concentrat-
ing and acidification defects, with few clinical manifesta-
tions [14].
In ACL there are very few studies regarding renal func-
tion evaluation, and the renal abnormalities described
are linked to specific treatment with pentavalent antimo-
nials [15]. These drugs are described to cause acute
kidney injury due to hypersensitivity reaction [12]. Other
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possible mechanisms for kidney injury in ACL have not
been investigated by now.
A recent study conducted by our study group found
important abnormalities in ACL. Expression of the Na
+/H+ exchanger (NHE3), H+-ATPase, and pendrin were
all significantly higher in patients with ACL when com-
pared with normal subjects. A combined urinary con-
centration and acidification defect was found in 32.4% of
patients, before specific ACL treatment [16].
The aim of this study is to investigate if these tubular
abnormalities persist after specific ACL-treatment.
Methods
Patients
This is a prospective study with 37 patients with con-
firmed diagnosis of ACL (epidemiologic, clinical and
laboratorial) in a public health service in the city of Bar-
balha, Ceara, Brazil, between July 2008 and July 2009.
Exclusion criteria was patients under 15 years-old or
older than 60 years, use of pentavalent antimonials in
the last 30 days, hypertension (Systolic blood pressure ≥
140 or Diastolic blood pressure ≥ 90 mmHg), diabetes
mellitus, urinary tract infection, systemic lupus erythe-
matosus and other colagenosis, and previous kidney dis-
ease. The 37 patients were compared with 10 healthy
volunteers. The protocol of this study was revised
and approved by the Ethical Comitee of the Walter
Cantidio University Hospital, Federal University of
Ceara, Fortaleza, Brazil. Patients were included in the
study after signing the informed consent form.
Diagnosis of ACL
Diagnosis of ACL was based on epidemiologic and clin-
ical criteria, Montenegro skin test and identification of
parasite in tissue biopsy.
Clinical and laboratory parameters
At the time of medical consult all symptoms and signals
were evaluated, as well as race, age, gender, previous
chronic diseases, number of skin lesions, time of disease,
use of drugs, body mass index, blood pressure, Monte-
negro skin test, ACL classification. The following labora-
tory tests were studied in blood and plasma: urea (PUr),
creatinine (PCr),pH, (Posm) osmolality, bicarbonate
(BICs), sodium (PNa+), potassium (PK+), chloride (PCl-),
magnesium (PMg++), calcium (PCa++), phosphorus (PP-),
albumin/globulin, amilase, fast glucose, erythrocyte sedi-
mentation rate (ESR). In urine were studied the following
tests: creatinine and urea (UCr e UUr), sodium (UNa+),
potassium (UK+), chloride (UCl-), calcium (UCa++), phos-
phorus (UP-), magnesium (UMg++), microalbuminuria,
urinalysis, osmolality (Uosm) and pH (UpH).
Renal function evaluation
Glomerular filtration rate (GFR) was estimated through
the Cockroft & Gault formula and it was considered
abnormal when ≤ 90 ml/min/1,73 Body Surface Area m2.
In an isolated urine sample collected before concentra-
tion and acidification tests, pre- and post-glucantime
treatment sodium, potassium, chloride, magnesium and
microalbuminuria were measured.
All patients underwent food and water deprivation for
12 hours. Fraction excretion of sodium (FENa), potas-
sium (FEk), calcium (FECa), phosphorus (FEP), mag-
nesium (FEMg) were calculated by standard formula.
Microalbuminuria was measured in an isolated urine
sample and normalized by urinary creatinine.
Urinary concentration ability was evaluated through
the ratio between urinary and serum osmolality (U/Posm)
after 12 hours water deprivation, and urinary osmolality
(Uosm) was measured before and 4 hours after adminis-
tration of intranasal DDAVPW (desmopressin acetate
20mcg/kg - T0 and T4). Urinary acidification was evalu-
ated by the urinary pH before and after administration
of oral CaCl2 2 mEq/kg (T0 and T4). Acidification defect
was determined by the inability in decreasing UpH for
less than 5.50.
All patients underwent standard treatment with antim-
onial (GlucantimeW) in the dose of 20 mg/kg/day for
20 days. All tests were done before treatment and
4 weeks after the beginning of the treatment.
Groups definition
Pre-glucantime group – Tests performed before the
beginning of treatment.
Post-glucantime group – Tests performed 4 weeks
after the beginning of the treatment.
Analytical methods
Urea: Determined by colorimetric uricase method (Lab-
testW). The results were expressed in mg/dl. Serum and
urinary creatinine: Determined by colorimetric methods,
picric acid, Taussky and Bonsness (LabtestW). The results
were expressed in mg/dl. Serum and urinary Sodium
and potassium (PNa+ e PK+): Determined by photo-
metry technique with spectrophotometry, model B462
MICRONAL (Instrumentation Laboratory, Inc. USA).
The results were expressed in mEq/L. Albumin: Deter-
mined by bromocresol reaction (LabtestW). The results
were expressed in g/dl. Globulin: Determined by bromo-
cresol reaction (LabtestW). The results were expressed in
g/dl. Glucose: Determined by colorimetric glucose oxi-
dase method (LabtestW). The results were expressed in
mg/dl. Alkaline phosphatase: Determined by phosphat-
ase kinetic method, Bowers and Mc Comb modified
(LabtestW). The results were expressed in U/L. Amilase:
Determined by colorimetric Caraway modified method.
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Results expressed in U/dl. pH, bicarbonate (HCO3-):
were determined through “Blood gas analyser” machine
(chiron diagnostic 238 - BayerW). The results were
expressed in mEq/L for bicarbonate. Urinary pH (UpH):
measured by pHmetro Digital pG1000, model GEHA-
KALT. Urinary osmolarity: Determined by the technique
pressure steam in osmometer model 5100 C (Wescor
Inc., USA). The results were expressed in mOsm/Kg.
H2O. Microalbuminuria: measured through immunotur-
bidimetry methods, using Tina-quantW kit (Roche) and
the results were expressed in mcg/g creatinine.
Statistical analysis
All quantitative data are expressed as mean ± SEM. Dif-
ferences between two parameters were analyzed either
by paired Student t test or by nonparametric methods
(Wilcoxon test and Mann–Whitney test). Chi-square
test was used to analyze categoricalvariables. Values of
P< 0.05 were considered statistically significant.
Results
Of the 59 patients enrolled in the study with previously
diagnosed of ACL on the basis of epidemiological, clin-
ical, biochemical, and histopathological findings 22 were
excluded: eight for testing negative on a new histopatho-
logical exam; nine for being under 15 years of age or
over 60 years of age; two for subsequently declining to
participate in the study; one for having hypertension;
one for having diabetes mellitus; and one for having used
an antimonial (meglumine antimoniate) within the last
30 days. Therefore, the study group included 37 ACL
patients who agree to participate. The mean age was
35.6 ± 12 years and 19 (51.4%) were male. Clinical and
demographic data were similar between ACL patients
and controls (Table 1).
Montenegro skin test was positive in 59.5% of cases.
All patients have ACL in its isolated cutaneous type, 27
had a solitary skin lesion, 7 had 2–4 lesions and 3 had
more than 4 lesions. The mean time of disease was
28.5 ± 20.6 days (range 7–90 days).
The laboratory evaluation, before and after treatment
with pentavalent antimonial, is shown in Table 2. It was
observed only a mild decrease in hemoglobin post-
treatment. In biochemical analysis it was noted an in-
crease in aminotransferases (p< 0.05) after treatment.
No one patient presented increase in serum amylase
with treatment.
There was no significant glomerular filtration abnor-
mality before and after treatment (109.6 ± 32 vs. 109.6 ±
28 ml/min/1.73 m2, P= 0.694). Microalbuminuria was
23.6 ± 26 mg/g creatinine, before treatment, and
14.6 ± 18.9 mg/g creatinine after treatment (p = 0.02).
Urinary concentrating defect, based on U/Posm (<2,8),
was observed in 27 patients before treatment and in 30
after treatment (77% vs. 88%, p = 0,344), with no signifi-
cant difference between pre and post-treatment (2.2 ±
0.7 vs. 1.9 ± 0.75, P= 0.718) (Table 3).
Urinary acidification defect, defined as the inability to
reduce urinary pH to< 5.5 after CaCl2 administration,
was observed in 15 patients before treatment and in only
6 after treatment (40% vs 16%, p = 0.012), with signifi-
cant difference when comparing the pH values before
and after treatment (5.50 ± 0.64 vs. 5.19 ± 0.60,
P= 0.0066). After treatment, 18 among 36 patients (50%)
presented PHCO3- <21 mEq/L, and pH <7.35 was seen
Table 1 Clinical and demographic data of patients with
ACL compared with healthy subjects
Characteristics ACL
(n = 37)
Control
(n = 10)
P
Age (years) 35.6 ± 12 32.3 ± 11.7 0.442
Gender
Male 19 (51.4%) 6 (60%) 0.73
Female 18 (48.6%) 4 (40%)
Time of disease (days) 28.5 ± 20.6 - -
Montenegro skin test (+/−) 22/37 - -
Number of skin lesions
1 27 (72.9%) - -
2 to 4 7 (18.9%) - -
>4 3 (8.1%)
Systolic blood pressure, mmHg 122 ±10 117 ± 9.5 0.221
Diastolic blood pressure, mmHg 80 ± 4.7 75 ± 8.5 0.079
Data expressed as mean ± standard deviation or %. Student t test.
Table 2 Laboratory data of 37 patients with ACL before
and after specific treatment
Pre-treatment Post-treatment P
Hematocrit (%) 42.6 ± 4.1 40.5 ± 4.2 0.0052
Hemoglobin (g/%) 13.9 ± 1.2 13.3 ± 1.5 0.019
White blood count (/mm3) 6.359 ± 1918 6.035 ± 1513 0.269
Platelets (/mm3) 275.351 ± 66.259 292.702 ± 60.570 0.074
Arterial pH 7.35 ± 0.1 7.35 ± 0.1 0.634
Fasting glucose (mg/dl) 80 ± 15 80 ± 17 0.915
Amylase (U/dl) 143 ± 48 148 ± 62 0.666
Total Bilirubin (mg/dl) 0.5 ± 0.27 0.6 ± 0.23 0.810
Alkaline Phosphatase (U/L) 93 ± 33 107 ± 52 0.08
Albumin (g/dl) 4 ± 0.6 4 ± 0.6 0.696
Globulin (g/dl) 3.3 ± 0.86 3.3 ± 0.7 0.135
AST (g/dl) 34 ± 15 46 ± 36 0.034
ALT (U/L) 28 ± 19 42 ± 33 0.023
ESR (mm/h) 30 ± 21 26 ± 18 0.198
Significant P< 0.05. AST: aspartate aminotransferase; ALT: alanine
aminotransferase; ESR: erythrocyte sedimentation rate. Data expressed as
mean ± standard deviation or %. T test and Wilcoxon test.
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in 42% cases. Regarding excretion fractions (FENa, FEk,
FECa, FEP and FEMg) there was no significant differ-
ences in the values before and after treatment (Table 4).
FENa+> 2% was found in 4 patients (10.8%), FEk+> 10%
in 11 patients (29.7%), FECa++> 3% in 2 patients (5.4%),
FEPO4-> 10% in 10 patients (29%) and FEMg++> 6% in
only 1 patient (2.7%).
None of the patients presented severe adverse reactions
to the pentavalent antimonial. Among the 37 studied
cases, 5 (13.5%) presented low degree fever, myalgia and
asthenia, and one patient had arthralgia and headache.
Discussion
The results of the present study evidence the occurrence
of asymptomatic tubular dysfunction probably induced by
ACL and that partially improved after specific treatment.
All patients studied had ulcerated lesions. They were
in very early stages of the disease, however they pre-
sented systemic inflammatory reactions, such as fever,
arthralgias and myalgias, which have been previously
reported [17]. This can lead to humoral activation, which
can explain the finding of renal tubular dysfunction.
In the present study, the number of patients with
ClCr< 90 ml/min/1.73 m
2 did not present significant
difference before and after treatment with pentavalent
antimonial (11 among 37 before treatment and 12
among 37 after treatment). Previous reports on the renal
involvement in ACL have linked renal abnormalities to
the use of these drugs, as acute kidney injury by tubu-
lointerstitial nephritis or reaction Jarish-Herxheimer like,
which is not in accordance to our findings [12,15].
Renal dysfunction in visceral leishmaniasis (kala-azar)
has been described [7-10,18]. Lima Verde et al [14]
in a study with 50 patients with kala-azar found
GFR< 80 ml/min/1.73 m2 in 14 cases (28%). In another
study, including 224 patients with kala-azar, acute kidney
injury was found in 76 cases (33.9%) and this complica-
tion was associated with increased mortality [10]. In a re-
cent study by Daher et al [19], renal tubular dysfunction
in kala-azar significantly improved after treatment with
pentavalent antimonial. After specific treatment, all
patients in the present study still remained with urinary
concentrating and two-thirds improved previous acidifi-
cation defects, suggesting that the tubular damage can
be irreversible.
In our study microalbuminuria higher than 30 mg/g
was found in 35% of patients before treatment and
in only 8% after treatment, suggesting that glomerular
lesion in ACL could have been caused by the parasitic
disease per se, but without GFR reduction. In a study
with 11 patients with kala-azar, 8 presented increased
microalbuminuria (81.8%), which is higher than that
found in ACL [7]. Elnojomi et al [20] detected abnormal
microalbuminuria in 35 out of 88 (40%) patients with
kala-azar, with no glomerular dysfunction. Microalbumi-
nuria can also be found in other infectious diseases that
affect the skin and nerves, such as leprosy. Oliveira et al
[21] identified microalbuminuria in 4 out of 59 patients
with multibacillary leprosy (8.5%). A higher prevalence
Table 3 Glomerular and tubular function of 37 patients
with ACL before and after specific treatment
Pre-
glucantime
(N= 37)
Post-
glucantime
(N= 37)
Control
(N= 10)
Pcreat , (mg/dl) 0.81 ± 0.16 0.81 ± 0.15 0.85 ± 0.18
CrCl (ml/min/1.73 m2) 109.6 ± 31.5 108.4 ± 28.5 116.4 ± 22.7
U/Posm T4 2.19 ± 0.73 1.95 ± 0.73 3.47 ± 0.33
UpH T4 5.45 ± 0.64 5.19 ± 0.60
* 4.82 ± 0.20 #
Uosm T4 618 ± 202 552 ± 210 965 ± 81
#
FENa, (%) 1.15 ± 0.74 1.35 ± 1.51** 0.73 ± 0.39
FEk, (%) 10 ± 6.6 10.1 ± 7.6 7.50 ± 2.8#
FECa (%) 1.07 ± 0.72 1.32 ± 1.01 0.62 ± 0.34#
FEPO4 (%) 10.9 ± 9.98 10.9 ± 15.7 9.10 ± 6.4
FEMg (%) 1.81 ± 1.70 1.90 ± 1.44 0.90 ± 0.40#
Microalbuminuria
(mg/g creatinine)
23.6 ± 26*** 14.6 ± 18.9 6.12 ± 4.06
* Pre vs. Post-glucantime, p = 0.0066; # control vs. Pre and post-glucantime,
p< 0.05; **Post-glucantime vs. control, p = 0.048; ***pre vs. post-glucantime,
p = 0.025. DATA: MEAN± SD. Student t test, Mann–Whitney.
Pcrea – SerumCreatinine.
CrCl – Creatinine clearance.
U/Posm – Urinary and serum osmolarity ratio.
UpH em T4 – Urinary pH in T4.
Uosm T4 – Urinary osmolality in T4.
FE: fraction excretion.
Table 4 Prevalence of renal dysfunction in 37 patients
with ACL before and after specific treatment
Pre-
treatment
Post-
treatment
P
Pcreat >1.2 mg/dl - - -
CrCl <90 ml/min/1.73 m2 11 (30%) 12 (32%) 1.000
Microalbuminuria>30 mg/g creat 12 (39%) 3 (10%) 0.004
Uosm T4<700mmOsm/kg H2O 21 (62%) 24 (71%) 0.508
U/Posm T4<2.8 26 (77%) 30 (88%) 0.344
UpH T4>5.5 15 (40%) 6 (16%) 0.012
EFNa+>2% 5 (14%) 4 (11%) 1.000
EFk+>10% 12 (32%) 11(30%) 1.000
EFCa++>3% 2 (5%) 2 ( 5%) 1.000
EFPO4->10% 17 (46%) 10 (27%) 0.143
EFMg++>6% 1 (2.7%) 1 (2.7%) 1.000
Pcrea – plasma creatinine; CrCl – creatinine clearance; U/Posm – urine and
plasma osmolarity ratio; UpH T4 – urine pH in T4 (4 hours after CaCl2
administration); Uosm T4 – urine osmolariry in T4 (4 hours after DDAVP
administration); EFNa – Sodium excretion fraction; EFK – Potassium excretion
fraction; EFCa – Calcium excretion fraction; EFMg – Magnesium excretion
fraction. Data expressed as percentage (%).
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of microalbuminuria was found in another study involv-
ing leprosy patients. Kirsztajn et al [22]. identified
microalbuminuria higher than 20 mg/l in 15.8% of 96
patients with leprosy. In the present study we observed a
decrease in microalbuminuria after treatment, which
suggests that ACL per se can lead to increased urinary
albumin loss. However microalbuminuria is not yet a
well defined marker of glomerular dysfunction in infec-
tious diseases.
In the present study, the urinary concentrating ability
was evaluated by the ratio U/Posm and Uosm, measured
after 12 h water deprivation and fasting, which was sen-
sitized by the administration of DDAVP. Urinary con-
centration deficit was found in 27 cases (77%) before
treatment and in 31 (88%) after treatment (p = 0.344).
There was also no significant difference in the values
of Uosm after the administration of DDAVP before and
after treatment (p = 0.508). Based on these findings we
can suggest that ACL per se can cause urinary concen-
trating deficit. The specific treatment did not improve
this abnormality, but do not allow a worsening in the
tubular lesion.
In a study involving 11 patients with ACL treated with
pentavalent antimonial, 40 mg/kg for 30 days, the per-
sisting urinary concentrating deficit was observed in 8
cases (72.7%) [23]. Veiga et al [24], reported 5 cases of
ACL treated with pentavalent antimonial in conventional
doses, but with a longer duration, which developed urin-
ary concentrating inability. Lima Verde et al [14], found
68% of urinary concentrating capacity defect in patients
with kala-azar before pentavalent antimonial therapy.
The persistence of this abnormality can be a conse-
quence of ACL itself, which can cause a severe tubular
damage. Further investigations, with a longer period of
observation after ACL treatment, would be important to
establish the long-term outcomes regarding this compli-
cation. Maybe urinary concentrating ability can be
restored with time in this group of patients.
In the present study urinary acidification defect was
found in 40% of the patients before treatment and in
16% after treatment, which suggests an important im-
provement in acidification ability after specific treatment
for ACL. Urinary acidification deficit is less common
than concentration deficit. In a study with patients with
kala-azar, urinary acidification defect was found in 64%
of cases after specific treatment [14].
Conclusions
Renal abnormalities detected in ACL improve partially
after specific treatment, especially microalbuminuria and
urinary acidification. The persistent urinary concentrant-
ing deficit may be related to a permanent damage
induced by ACL or maybe an overlap effect of the treat-
ment and the disease. Further studies are required to
better understand the mechanisms involved in tubular
dysfunction caused by ACL and by the treatment.
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